distribution agreement

The test is designed to detect clinically relevant genomic alterations — including somatic mutations, microsatellite instability, and viral DNA from ctDNA — in blood.

The firm signed four new distribution deals to spread its products into more than a dozen new markets.

Nikon will distribute OptraScan's whole-slide imaging scanners, as well as its integrated telepathology, and AI- and machine learning-based analytics solutions.

OncoDNA anticipates a strong increase in the use of OncoDNA profiling products in Europe with the partnerships with Gammaray and AMS.

The deal covers Cancer Genetics' microarray-based Tissue of Origin test, which analyzes 2,000 individual tumor genes to help identify a tumor's origin.

The three-year extension increases the minimum purchase commitments for the Unyvero system, resulting in an increase in potential revenues of €30 million to Curetis.

Immunoscore Colon predicts the risk of recurrence in patients with early-stage colon cancer and guides oncologists in decisions about therapies for stage II and III colon cancers.

The tests are based on a technology that uses Fourier transform infrared spectroscopy and a proprietary technique that analyzes spectrometer test results.

TSG is a wholly owned subsidiary of Ascendis Medical and supplies diagnostic laboratory equipment and consumables to pathology laboratories.

Lucence's test are designed to detect DNA fragments shed by a tumor into the blood and target the most common cancers in Asia such as lung cancer.